New combo therapy aims to boost liver cancer surgery success
NCT ID NCT07154082
Summary
This study is testing a combination of two drugs (apatinib and camrelizumab) plus a procedure called TACE as a treatment given before surgery for liver cancer. The goal is to shrink the tumor first, making it easier to remove completely during surgery and hopefully lowering the chance of the cancer coming back later. The study will enroll about 27 adults with a specific type of liver cancer that is located centrally in the liver and is considered operable.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.